American Cancer Society reaffirms Cologuard as preferred option

Abbott said updated American Cancer Society guidelines reaffirm Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options for adults 45+ at average risk, with both tests recommended every three years. Cologuard Plus is cited as detecting 95% of colorectal cancers at 94% specificity, and Abbott also announced a pending commercialization agreement for a Freenome blood-based test. The article also notes mixed analyst reactions after Abbott's Q1 results, with several firms cutting price targets to $106-$115.

Analysis

The near-term read-through is not just sentiment support for ABT, but a re-rating of durability in its diagnostics franchise. Preferred guideline status materially lowers commercial friction, and because screening is a multi-year habit, even modest share gains compound into recurring installed-base economics rather than one-time kit sales. The more interesting second-order effect is that this strengthens ABT’s negotiating leverage with payers and health systems just as investors are punishing the stock for slower organic growth elsewhere.

The market is likely underestimating the asymmetry between diagnostics optionality and the rest of the portfolio. If the blood-based test clears FDA, ABT could control a tiered screening funnel: home stool testing for the mainstream, blood-based capture for non-adopters, and downstream follow-on procedures. That creates a broader addressable population without requiring a breakthrough in test performance, which is why the real catalyst is not the current guideline language but the conversion of guideline endorsement into reimbursement and care-pathway inclusion over the next 6-18 months.

The bearish case is that this is being treated as a headline-positive but numerically small event versus the larger issue of decelerating core growth and weak diabetes execution. If management cannot show that diagnostics can offset margin pressure or lost momentum in other categories, the stock can remain a value trap despite favorable product news. The key reversal risk for the bull case is a lack of payer adoption or a slower-than-expected FDA timeline for Freenome, which would push the optionality further out and keep the multiple depressed.

Consensus appears too focused on the recent analyst target cuts and too little on the fact that ABT now has multiple independent catalysts in 2025: guideline support, AI imaging clearance, and a potential new screening modality. That combination makes the stock more interesting as a self-help/re-rating story than a pure earnings growth story. The setup favors buying weakness if the market sells the news, because the downside from here is more likely to be time-based than thesis-based.

Key Decisions for Investors

• Long ABT on weakness over the next 1-3 weeks; use current multi-month pessimism as entry, targeting a 10-15% rebound if the market starts pricing diagnostics durability rather than quarterly growth noise. Risk: if the next print confirms broad-based deceleration, the multiple can stay compressed for another 2-3 quarters.
• Buy ABT Jan-2026 calls or call spreads to express the re-rating through 12-18 months of catalyst timing. Best risk/reward is a spread that benefits from a gradual rerating rather than an immediate breakout, since payer/FDA milestones are not overnight events.
• Pair long ABT / short a higher-multiple healthcare equipment name with less self-help and fewer product catalysts over the next 6 months. The thesis is that ABT’s discounted valuation plus multiple shots on goal should outperform peers if growth is merely stabilizing.
• If Freenome FDA progress becomes visible, add aggressively; that is the highest convexity catalyst because it expands the funnel beyond the current stool-test market. Until then, size the position as a quality compounder with event risk, not as a straight-line growth trade.